[go: up one dir, main page]

SI2007752T1 - Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja - Google Patents

Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja

Info

Publication number
SI2007752T1
SI2007752T1 SI200730395T SI200730395T SI2007752T1 SI 2007752 T1 SI2007752 T1 SI 2007752T1 SI 200730395 T SI200730395 T SI 200730395T SI 200730395 T SI200730395 T SI 200730395T SI 2007752 T1 SI2007752 T1 SI 2007752T1
Authority
SI
Slovenia
Prior art keywords
benzoimidazol
pyrazines
pyrimidines
histamine
modulators
Prior art date
Application number
SI200730395T
Other languages
English (en)
Inventor
James P Edwards
David E Kindrachuk
Jennifer D Venable
Christopher M Mapes
Daniel J Pippel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38581554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2007752(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SI2007752T1 publication Critical patent/SI2007752T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
SI200730395T 2006-03-31 2007-03-30 Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja SI2007752T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78819006P 2006-03-31 2006-03-31
PCT/US2007/008216 WO2007117399A2 (en) 2006-03-31 2007-03-30 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
EP07754700A EP2007752B1 (en) 2006-03-31 2007-03-30 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor

Publications (1)

Publication Number Publication Date
SI2007752T1 true SI2007752T1 (sl) 2010-12-31

Family

ID=38581554

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730395T SI2007752T1 (sl) 2006-03-31 2007-03-30 Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja

Country Status (34)

Country Link
US (6) US7507737B2 (sl)
EP (1) EP2007752B1 (sl)
JP (1) JP5066175B2 (sl)
KR (1) KR101054325B1 (sl)
CN (1) CN101460483B (sl)
AR (1) AR059380A1 (sl)
AT (1) ATE478067T1 (sl)
AU (1) AU2007235576B2 (sl)
BR (1) BRPI0710083A2 (sl)
CA (1) CA2648036C (sl)
CO (1) CO6160328A2 (sl)
CR (1) CR10413A (sl)
CY (1) CY1111169T1 (sl)
DE (1) DE602007008545D1 (sl)
DK (1) DK2007752T3 (sl)
EA (1) EA016264B1 (sl)
EC (1) ECSP088815A (sl)
ES (1) ES2348829T3 (sl)
IL (2) IL194453A0 (sl)
ME (1) ME01143B (sl)
MX (1) MX2008012655A (sl)
NI (1) NI200800260A (sl)
NO (1) NO341523B1 (sl)
NZ (1) NZ571691A (sl)
PE (1) PE20080130A1 (sl)
PL (1) PL2007752T3 (sl)
PT (1) PT2007752E (sl)
RS (1) RS51423B (sl)
SI (1) SI2007752T1 (sl)
TW (1) TWI400234B (sl)
UA (1) UA95949C2 (sl)
UY (1) UY30253A1 (sl)
WO (1) WO2007117399A2 (sl)
ZA (1) ZA200809328B (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710083A2 (pt) 2006-03-31 2011-08-02 Janssen Pharmaceutica Nv entidade quìmica benzoimidazol-2-il pirimidina e pirazina, composição farmacêutica e uso destas
EP2004188B1 (en) * 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
US20090069343A1 (en) * 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8084466B2 (en) * 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
NZ589531A (en) * 2008-06-12 2012-08-31 Janssen Pharmaceutica Nv Use of histamine H4 antagonist for the treatment of post-operative tissue adhesions after surgical procedures
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
AU2013204436B2 (en) * 2008-06-30 2014-12-04 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
SI2310012T1 (sl) 2008-06-30 2015-06-30 Janssen Pharmaceutica N.V. Postopek za pripravo substituiranih pirimidinskih derivatov
NZ590169A (en) * 2008-06-30 2012-05-25 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US9006454B2 (en) * 2009-04-02 2015-04-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US20140187533A1 (en) * 2011-03-03 2014-07-03 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SI2858647T1 (sl) 2012-06-08 2018-11-30 Sensorion Inhibitorji receptorja H4 za zdravljenje tinitusa
HUE047681T2 (hu) * 2013-03-06 2020-05-28 Janssen Pharmaceutica Nv A hisztamin H4 receptor benzimidazol-2-il-pirimidin modulátorai
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
AU2022349020A1 (en) 2021-09-27 2024-05-09 Terns Pharmaceuticals, Inc. Benzimidazole carboxylic acids as glp-1r agonists
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JP2025508812A (ja) 2022-02-23 2025-04-10 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒアゴニストとしての化合物
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US3931195A (en) 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
US4191828A (en) 1976-04-14 1980-03-04 Richardson-Merrell Inc. Process for preparing 2-(2,2-dicyclohexylethyl)piperidine
US4337341A (en) 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
US4190601A (en) 1978-05-31 1980-02-26 Union Carbide Corporation Production of tertiary amines by reductive alkylation
JPS5942396A (ja) 1982-09-02 1984-03-08 Ishihara Sangyo Kaisha Ltd リン酸アミド誘導体およびそれらを含有する殺虫、殺ダニ、殺線虫剤
JPS6130576A (ja) 1984-07-24 1986-02-12 Ube Ind Ltd ２−アミノ−５−シアノピリミジンの製法
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9410031D0 (en) * 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
JP2000507591A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
EP0891357A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU729869B2 (en) 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
WO1999018079A1 (en) 1997-10-06 1999-04-15 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
ATE242241T1 (de) 1999-03-25 2003-06-15 Synthon Bv Imidazopyridinderivate und verfahren zu ihrer herstellung
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
HRP20010944B1 (hr) 1999-06-23 2010-08-31 Sanofi-Aventis Deutschland Gmbh Supstituirani benzimidazoli
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
CZ20023775A3 (cs) 2000-04-24 2003-10-15 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrát
AU2001268711A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
EP1301491A1 (en) 2000-07-21 2003-04-16 Syngenta Participations AG Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
WO2002042272A2 (en) * 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
AU2002247402A1 (en) 2001-03-23 2002-10-08 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
US20050107400A1 (en) 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
EP1408986B1 (en) * 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
KR100898894B1 (ko) 2001-11-05 2009-05-21 메르크 파텐트 게엠베하 히드라조노-말로니트릴
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
DE60326735D1 (de) 2002-08-02 2009-04-30 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
US20040127395A1 (en) 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7226938B2 (en) 2002-09-06 2007-06-05 Janssen Pharmaceutica, N.V. Heterocyclic compounds
CN1694704A (zh) 2002-09-06 2005-11-09 詹森药业有限公司 （1h－苯并咪唑－2－基）－（哌嗪基）－甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病
CA2497829A1 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Method to treat allergic rhinitis
JP2006510597A (ja) * 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040105856A1 (en) 2002-12-02 2004-06-03 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
AU2003297629A1 (en) 2002-12-04 2004-06-23 Ore Pharmaceuticals Inc. Modulators of melanocortin receptor
CN100372851C (zh) 2003-05-05 2008-03-05 弗·哈夫曼-拉罗切有限公司 具有crf活性的稠合的嘧啶衍生物
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
US20050054663A1 (en) 2003-08-13 2005-03-10 Bennett Christina N. GSK-3 inhibitors
US7781595B2 (en) * 2003-09-22 2010-08-24 S*Bio Pte Ltd. Benzimidazole derivatives: preparation and pharmaceutical applications
ES2323178T3 (es) 2003-09-30 2009-07-08 Janssen Pharmaceutica Nv Compuestos de benzoimidazol.
JP2007507514A (ja) 2003-09-30 2007-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノキサリン化合物
US7115646B2 (en) 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
US8277831B2 (en) 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
MXPA06011021A (es) * 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
CN1960977B (zh) 2004-05-31 2010-07-21 万有制药株式会社 喹唑啉衍生物
WO2006004791A1 (en) * 2004-06-30 2006-01-12 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
US7718801B2 (en) 2004-08-31 2010-05-18 Banyu Pharmaceutical Co., Ltd. Substituted imidazole derivative
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
CN101119973B (zh) 2004-12-17 2011-08-03 默克弗罗斯特加拿大有限公司 作为mPGES-1抑制剂的2-(苯基或者杂环基)-1H-菲并[9,10-d]咪唑类化合物
WO2006102645A1 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica, N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8193206B2 (en) * 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
KR101326438B1 (ko) 2005-07-06 2013-11-07 지이 헬스케어 바이오-사이언시스 에이비 분리 매트릭스의 제조 방법
AU2006290715A1 (en) 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
ATE533485T1 (de) 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
EP1956009A1 (en) * 2005-12-02 2008-08-13 Mitsubishi Tanabe Pharma Corporation Aromatic compound
JP2009527508A (ja) 2006-02-24 2009-07-30 メルク フロスト カナダ リミテツド ２−（フェニル又は複素環）−１ｈ−フェナントロ［９，１０−ｄ］イミダゾール
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
EP2004188B1 (en) 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
BRPI0710083A2 (pt) * 2006-03-31 2011-08-02 Janssen Pharmaceutica Nv entidade quìmica benzoimidazol-2-il pirimidina e pirazina, composição farmacêutica e uso destas
EP2010172B1 (en) 2006-04-07 2012-08-29 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
US20090069343A1 (en) 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
US20090192158A1 (en) 2006-05-02 2009-07-30 Stacia Kargman Methods for Treating or Preventing Neoplasias
JP2009537460A (ja) 2006-05-18 2009-10-29 メルク フロスト カナダ リミテツド ｍＰＧＥＳ−１阻害剤としてのフェナントレン誘導体
EP2040549B1 (en) 2006-07-11 2013-10-23 Janssen Pharmaceutica NV Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
PE20091035A1 (es) 2007-11-30 2009-07-16 Palau Pharma Sa Derivados de 2-aminopirimidina
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
US20090181242A1 (en) 2008-01-11 2009-07-16 Enniss James P Exterior window film
NZ589531A (en) 2008-06-12 2012-08-31 Janssen Pharmaceutica Nv Use of histamine H4 antagonist for the treatment of post-operative tissue adhesions after surgical procedures
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
NZ590169A (en) 2008-06-30 2012-05-25 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
SI2310012T1 (sl) 2008-06-30 2015-06-30 Janssen Pharmaceutica N.V. Postopek za pripravo substituiranih pirimidinskih derivatov
WO2010025314A2 (en) 2008-08-28 2010-03-04 The General Hospital Corporation Prevention and treatment of itch with cysteine protease inhibition
TWI519533B (zh) 2010-11-01 2016-02-01 Ｌｇ生命科學有限公司 １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物
EP2465498A1 (en) 2010-11-23 2012-06-20 Faes Farma, S.A. Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
HUE047681T2 (hu) 2013-03-06 2020-05-28 Janssen Pharmaceutica Nv A hisztamin H4 receptor benzimidazol-2-il-pirimidin modulátorai

Also Published As

Publication number Publication date
UY30253A1 (es) 2007-08-31
TWI400234B (zh) 2013-07-01
AU2007235576A1 (en) 2007-10-18
CN101460483A (zh) 2009-06-17
ATE478067T1 (de) 2010-09-15
ECSP088815A (es) 2008-11-27
NO341523B1 (no) 2017-11-27
PL2007752T3 (pl) 2011-02-28
NO20084540L (no) 2008-10-28
IL244946A0 (en) 2016-05-31
US20140038995A1 (en) 2014-02-06
CR10413A (es) 2009-02-19
PE20080130A1 (es) 2008-02-25
UA95949C2 (ru) 2011-09-26
CA2648036C (en) 2012-05-22
EP2007752A4 (en) 2009-04-22
US20100256373A1 (en) 2010-10-07
CA2648036A1 (en) 2007-10-18
IL244946A (en) 2017-03-30
JP2009532366A (ja) 2009-09-10
EA016264B1 (ru) 2012-03-30
EP2007752A2 (en) 2008-12-31
EP2007752B1 (en) 2010-08-18
WO2007117399A3 (en) 2008-09-12
MX2008012655A (es) 2008-12-16
KR101054325B1 (ko) 2011-08-04
TW200808737A (en) 2008-02-16
WO2007117399A2 (en) 2007-10-18
JP5066175B2 (ja) 2012-11-07
BRPI0710083A2 (pt) 2011-08-02
RS51423B (sr) 2011-02-28
DK2007752T3 (da) 2010-11-15
ES2348829T3 (es) 2010-12-15
IL194453A0 (en) 2009-08-03
AR059380A1 (es) 2008-04-09
US20070244126A1 (en) 2007-10-18
NZ571691A (en) 2011-07-29
US8343989B2 (en) 2013-01-01
PT2007752E (pt) 2010-10-18
US20130072510A1 (en) 2013-03-21
NI200800260A (es) 2012-01-24
CN101460483B (zh) 2013-05-08
US8598189B2 (en) 2013-12-03
KR20080108586A (ko) 2008-12-15
US7507737B2 (en) 2009-03-24
DE602007008545D1 (de) 2010-09-30
US20090137608A1 (en) 2009-05-28
EA200870400A1 (ru) 2009-04-28
US20150148361A1 (en) 2015-05-28
AU2007235576B2 (en) 2011-11-10
US8962644B2 (en) 2015-02-24
CY1111169T1 (el) 2015-06-11
US9365548B2 (en) 2016-06-14
CO6160328A2 (es) 2010-05-20
ME01143B (me) 2013-03-20
ZA200809328B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
IL244946A (en) Pyrimidine and pyrazine compounds converted to benzoimidazol-2-il, as histamine h4 receptor modulators
IL200335A0 (en) 2-aminopyrimidine modulators of the histamine h4 receptor
IL196448A0 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
EP2010172A4 (en) INDOLE AND BENZOIMIDAZOLE AS HISTAMINE H4 RECEPTOR MODULATORS
IL250847A0 (en) 5-substituted quinazolinone derivatives as anticancer agents
ZA200903495B (en) Substituted pyrimidines and their use as JNK Modulators
ZA201100298B (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
ZA200808191B (en) Pyridine and pyrimidine derivatives as MGLUR2 antagonists
IL178597A0 (en) Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
EP2200595A4 (en) THIENO AND FURO PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR
EP2114903A4 (en) BICYCLIC PYRIMIDINONES AND USES THEREOF
ZA201005179B (en) 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
EP2061470A4 (en) HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES
ZA200904321B (en) Bicyclic pyrimidinones and uses thereof
HK1138154A (en) 2-aminopyrimidine modulators of the histamine h4 receptor
HK1122035A (zh) 作为组胺h1和h3拮抗剂的2-取代的4-苯基二氮杂萘酮衍生物
HK1131336A (en) Urotensin ii receptor antagonists
HK1126118A (en) Urotensin ii receptor antagonists
HK1130480A (en) Substituted benzamide modulators of the histamine h3 receptor
HK1130471A1 (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor